Overview: In a new deal reached on Friday, Bayer has agreed to pay up to $24 million to settle Yaz and Yasmin lawsuits alleging gallbladder injuries, Reuters reports. The company, who is facing some 8,000 gallbladder claims, has already agreed to pay $1 billion to settle lawsuits alleging that the birth control pills caused blood clots that lead to heart attack, stroke and death. Bayer has been faced with mounting litigation over Yaz and Yasmin since 2009.
- Bayer has agreed to settle some 8,000 Yaz and Yasmin lawsuits alleging gallbladder injuries; women who suffered gallbladder injuries would receive $2,000 and those who had their gallbladder removed would receive $3,000
- Bayer has already agreed to pay $1 billion to settle 4,800 blood clot claims
- There are over 10,000 lawsuits over Yaz and Yasmin; litigation has been mounting since 2009
Product: Yaz®, Yasmin® (Drospirenone and Ethinyl Estradiol)
Manufacturer: Bayer AG
Side Effects & Complications
- Blood Clots
- Pulmonary Embolism (PE)
- Deep Vein Thrombosis (DVT)
- Gallbladder Damage
- Heart Attacks
According to Reuters, Plaintiff who suffered from gallbladder injuries would receive $2,000 and those who had their gallbladder removed would receive $3,000. Bayer is able to deny the settlement if fewer than 90 percent of eligible individuals choose to participate in the settlement. The company, who is facing over 10,000 lawsuits over Yaz and Yasmin, agreed to settlement without admission of liability. The company has been faced with an increasing number of lawsuits over the oral contraceptives since 2009. According to Plaintiff’s attorneys, women who suffered both blood clot and gallbladder injuries should not opt for the gallbladder settlement since settlements for blood clot injuries tend to be much larger; damages can amount to over $100,000 per case.
Yaz, Yasmin Blood Clot Lawsuits
Yaz and Yasmin have raised a number of safety concerns due to reports that they can increase the risk of blood clots, which can lead to heart attack, stroke and death. This new generation of birth control pills contains a synthetic hormone known as drospirenone, which is thought to be the main factor for an increased risk of thromboembolic events. Last April, the U.S. Food and Drug Administration (FDA) updated the labels on Yaz, Yasmin and other birth control pills containing drospirenone to warn about the increased risk of blood clots. The agency also funded a study showing that such oral contraceptives are associated with a 77 percent increased risk of blood clots in the veins and a 200 percent increased risk of blood clots in the arteries. In its annual report, the company said it has set aside $1.5 billion to cover the cost of litigation, including existing and anticipated future settlements.